Pharmaceuticals US

US Family Planning Products Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Family Planning Products Market Industry Trends and Forecast to 2034: Segmented by (Product, Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $6.77 Bn Placeholder estimate
Estimate 2025 $6.95 Bn 35% of the global market
Projected 2034 $8.84 Bn 27.1% Adds $1.88 Bn over 9 forecast years
CAGR 2025–2034 2.7% Faster than 13% of 180 Pharmaceuticals markets here
Key players 5
  • US is 35.04% of the global market.
  • In North America, the largest is US (this report) at $6.95 Bn.
  • Fastest growing: Canada at 5.1% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.88 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Family Planning Products Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $6.77 Bn — —
2025 (base) $6.95 Bn +$182.8 Mn —
2026 (forecast) $7.14 Bn +$187.7 Mn +2.7%
2027 (forecast) $7.33 Bn +$192.8 Mn +5.5%
2028 (forecast) $7.53 Bn +$198.0 Mn +8.3%
2029 (forecast) $7.74 Bn +$203.4 Mn +11.2%
2030 (forecast) $7.94 Bn +$208.9 Mn +14.2%
2031 (forecast) $8.16 Bn +$214.5 Mn +17.3%
2032 (forecast) $8.38 Bn +$220.3 Mn +20.5%
2033 (forecast) $8.61 Bn +$226.2 Mn +23.8%
2034 (forecast) $8.84 Bn +$232.3 Mn +27.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Family Planning Products Market Analysis at a glance
Market size, 2025$6.95 Bn placeholder estimate
Forecast, 2034$8.84 Bn placeholder estimate
Growth (CAGR), 2025–20342.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct and channel (see all)
Key playersBayer AG, Organon, Pfizer Inc., Mylan N.V., DKT International (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Family Planning Products Market Analysis Executive Summary

Family planning products help people choose if and when to have children, including pills, implants, injectables and IUDs.

Key segments of the family Planning Products market include product (Implants, Injectables and Oral Pills) and channel (Public Sector, Private Sector and NGOs).

Bar chart: US Family Planning Products market size, 2024–2034, placeholder estimates. $6.77 Bn in 2024, $6.95 Bn in 2025 and $8.84 Bn in 2034, 2.7% CAGR.
US Family Planning Products market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Family Planning Products Market Dynamics

Market Growth Drivers

Global health goals, donor and government funding, better mobile technology and focus on preventing disease are driving the family Planning Products market.

Opportunity

Digital tools for community health, local manufacturing and public-private partnerships give the family Planning Products market room to grow.

Market Restraints

Limited budgets, weak health systems in some regions, workforce shortages and supply chain gaps hold back the family Planning Products market.

Competitive Landscape for Family Planning Products Market in US

The family Planning Products market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Family Planning Products Market in US

Family Planning Products in the US: rules, payment and health figures

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] Contraception use: 74% of married women 15–49 in 2019, the latest World Bank figure for the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] World Bank Open Data, Contraception use (% of married women 15–49). Retrieved 17 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for family Planning Products. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Family Planning Products right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 17 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Family Planning Products in context

The US compared

  • Contraception use: 74% of married women 15–49 (2019).[1]
  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[2]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[3]

[1] World Bank Open Data, Contraception use (% of married women 15–49). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Family Planning Products market in the US?
Placeholder estimate: about $6.95 Bn in 2025, rising to about $8.84 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Family Planning Products market in the US growing?
Placeholder estimate: about 2.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Family Planning Products market report cover?
The report splits the market by product (Implants, Injectables, Oral Pills, IUDs and more) and channel (Public Sector, Private Sector, NGOs).
Who are the key players in the Family Planning Products market?
Key players include Bayer AG, Organon, Pfizer Inc., Mylan N.V. and DKT International.
What is driving the Family Planning Products market?
Global health goals, donor and government funding, better mobile technology and focus on preventing disease are driving the family Planning Products market.
Who regulates Family Planning Products in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
What does World Bank report for the US?
Contraception use: 74% of married women 15–49 in 2019, the latest World Bank figure. Source: World Bank Open Data, Contraception use (% of married women 15–49). Retrieved 17 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.
How much research is published on Family Planning Products?
PubMed lists 5,955 papers on Family Planning Products added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on contraception and women's health

See the topic